Acorda Therapeutics Inc (ACORQ)
OTCMKTS: ACORQ · Delayed Price · USD
0.780
+0.030 (4.00%)
Apr 26, 2024, 3:54 PM EDT - Market closed
Acorda Therapeutics Revenue
In the year 2023, Acorda Therapeutics had annual revenue of $117.63M, a decrease of -0.79%. Revenue in the quarter ending December 31, 2023 was $37.99M with 20.70% year-over-year growth.
Revenue (ttm)
$117.63M
Revenue Growth
-0.79%
P/S Ratio
0.01
Revenue / Employee
$1,153,265
Employees
102
Market Cap
821.03K
Revenue Chart
* The company reports in USD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 117.63M | -933.00K | -0.79% |
Dec 31, 2022 | 118.57M | -10.51M | -8.14% |
Dec 31, 2021 | 129.07M | -23.90M | -15.62% |
Dec 31, 2020 | 152.97M | -39.44M | -20.50% |
Dec 31, 2019 | 192.41M | -279.03M | -59.19% |
Dec 31, 2018 | 471.43M | -116.85M | -19.86% |
Dec 31, 2017 | 588.29M | 68.69M | 13.22% |
Dec 31, 2016 | 519.60M | 26.94M | 5.47% |
Dec 31, 2015 | 492.66M | 91.18M | 22.71% |
Dec 31, 2014 | 401.48M | 65.05M | 19.34% |
Dec 31, 2013 | 336.43M | 30.62M | 10.01% |
Dec 31, 2012 | 305.81M | 13.58M | 4.65% |
Dec 31, 2011 | 292.24M | 101.23M | 53.00% |
Dec 31, 2010 | 191.01M | 136.33M | 249.36% |
Dec 31, 2009 | 54.67M | 6.85M | 14.31% |
Dec 31, 2008 | 47.83M | 8.34M | 21.12% |
Dec 31, 2007 | 39.49M | 12.13M | 44.37% |
Dec 31, 2006 | 27.35M | 22.21M | 431.55% |
Dec 31, 2005 | 5.15M | 9.08M | -230.69% |
Dec 31, 2004 | -3.94M | -4.41M | -931.35% |
Jun 30, 2003 | 473.59K | 342.00K | 259.89% |
Dec 31, 2002 | 131.59K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 45.81B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
ACORQ News
- 12 days ago - Acorda Therapeutics Announces Delisting from Nasdaq - Business Wire
- 24 days ago - Acorda Therapeutics Announces Nasdaq Delisting Notification - Business Wire
- 26 days ago - Acorda Therapeutics shares sink nearly 40% after bankruptcy filing - Market Watch
- 26 days ago - Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement - Business Wire
- 26 days ago - Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024 - Business Wire
- 4 weeks ago - Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024 - Business Wire
- 3 months ago - Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025 - Business Wire
- 5 months ago - Acorda Therapeutics Reports Third Quarter 2023 Financial Results - Business Wire